AbbVie Stock News

Investing in dividend stocks allows you to earn dividend income, the best passive income stream. In August, we (my wife and I) received a dividend income total of $1,415.47. 2023 was up 24%. Eight months down in 2024 and the S&P 500 is still up 14%, despite the recent sell-offs. Unemployment is starting to tick up recently.

AbbVie's leadership and revenue mix have changed, and more change is coming. There's a good chance that it will diversify into a new pharmaceutical segment.

Full data from the primary analysis of the positive, single-arm Phase 2 PICCOLO trial, evaluating mirvetuximab soravtansine (ELAHERE®), for high folate receptor-alpha (FRα) expressing platinum-sensitive ovarian cancer (PSOC) (mini-oral presentation). Exploratory patient reported outcomes (PROs) from the Phase 2 LUMINOSITY trial, evaluating telisotuzumab vedotin (Teliso-V), a potential first-in-...

AbbVie is a Dividend King with solid growth prospects. Merck's looming patent cliff isn't as alarming as it might seem.

Salesforce today announced that its board of directors declared a quarterly cash dividend of $0.40 per share. The dividend is payable October 8, 2024, to stockholders of record on September 18, 2024.

NORTH CHICAGO, Ill. , Sept. 6, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share.

Pharmaceutical (PPH) stocks have done relatively well this year. The closely watched iShares US Pharmaceutical ETF (IHE) stock has jumped by 16.5%, slightly beating the S&P 500 index, which has risen by 16.3%.

Hims & Hers is rapidly picking up steam in the telehealth industry. UnitedHealth's dominance has created massive wealth for long-term investors.